Sharp Launches Clinventory IMS
Sharp, part of UDG Healthcare plc, has launched a new Inventory Management System (IMS) to support clinical trial sponsors in managing inventory and supplies.
The new system—named Clinventory—has been designed to provide full visibility of stock levels at investigator sites and tracking product through the supply chain.
Using the Clinventory IMS will also create efficiencies for trial sponsors by aiming to improve the drug management process by leveraging automation to increase reliability.
Sascha Sonnenberg, Global Head of Business Development at Sharp Clinical said “Clinventory has been designed specifically with those smaller-volume, early stage or open label clinical trials in mind, where a larger, more expensive inventory system might offer an array of functionality that is surplus to needs.”
Read the full release and learn more, here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
